维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

4篇 您的检索式：作者名="Andrew Weickhardt"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer显示文摘	Andrew J. Weickhardt Benjamin Scheier Joseph Malachy Burke Gregory Gan Xian Lu Paul A. Bunn Dara L. Aisner Laurie E. Gaspar Brian D. Kavanagh Robert C. Doebele D. Ross Camidge	2012	Journal of Thoracic Oncology2012，，12：	3
	2	A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer显示文摘	Andrew Weickhardt Robert Doebele Ana Oton Janice Lettieri DeLee Maxson Michele Reynolds Amy Brown Mary K. Jackson Grace Dy Araba Adjei Gerald Fetterly Xian Lu Wilbur Franklin Marileila Varella-Garcia Fred R. Hirsch Murry W. Wynes Hagop Youssoufian Alex Ad	2012	Journal of Thoracic Oncology2012，，2：	1
	3	分子检验的新时代,EGFR-TKI治疗的新时代显示文摘大约30年前,表皮生长因子受体(epithelial growth factor receptor,EGFR)被认为是癌症治疗较为合适的靶点[1-2]。随后,肿瘤学家尝试去观察部分恶性肿瘤细胞的增殖是否依赖于EGFR的激活以及相应细胞内酪氨酸激酶下游信号的传递。	Andrew J. Weickhardt Robert C. Doebele D. Ross Camidge 王欢欢孟茂斌	2013	国际病理科学与临床杂志2013，33，4：	0
	4	Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy显示文摘Oncogenic activation of the fibroblast growth factor receptor(FGFR)through mutations and fusions of the FGFR gene occur in a variety of different malignancies such as urothelial carcinoma and cholangiocarcinoma.Inhibition of the kinase domain of the FGFR with targeted oral FGFR inhibitors has been shown in both preclinical and early phase clinical trials to lead to meaningful reductions in tumour size and larger confirmatory randomized trials are underway.Acquired resistance to FGFR inhibition using a variety of mechanisms that includes,activation of alternate signaling pathways and expansion of tumour clones with gatekeeper mutations in the FGFR gene.This review summarizes the acquired resistance mechanisms to FGFR therapy and therapeutic approaches to circumventing resistance.	David K.Lau Laura Jenkins Andrew Weickhardt	2019	Cancer Drug Resistance2019，2，3：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费